KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Beginning Cash Balance: 2009-2024

Historic Beginning Cash Balance for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to $105.6 million.

  • Emergent BioSolutions' Beginning Cash Balance rose 314.42% to $267.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.7 million, marking a year-over-year increase of 87.82%. This contributed to the annual value of $105.6 million for FY2024, which is 83.57% down from last year.
  • As of FY2024, Emergent BioSolutions' Beginning Cash Balance stood at $105.6 million, which was down 83.57% from $642.6 million recorded in FY2023.
  • Emergent BioSolutions' Beginning Cash Balance's 5-year high stood at $642.6 million during FY2023, with a 5-year trough of $105.6 million in FY2024.
  • Moreover, its 3-year median value for Beginning Cash Balance was $576.3 million (2022), whereas its average is $441.5 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Beginning Cash Balance spiked by 270.26% in 2021, and later slumped by 83.57% in 2024.
  • Emergent BioSolutions' Beginning Cash Balance (Yearly) stood at $167.8 million in 2020, then soared by 270.26% to $621.3 million in 2021, then decreased by 7.24% to $576.3 million in 2022, then increased by 11.50% to $642.6 million in 2023, then plummeted by 83.57% to $105.6 million in 2024.